INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS

Since the discovery of the bactericidal activity of aminoglycosides, streptomycin, kanamycin, amikacin, and capreomycin (a macrocyclic peptide) have been widely used to treat tuberculosis and multidrug-resistant (MDR) tuberculosis. In general practice, resistance to kanamycin is often used as the sole criterion for defining extensively drug-resistant tuberculosis, assuming that all other drugs in this group or related drugs are resistant to certain strains. However, the assumption of cross-resistance between drugs in the same group is not always true for Mycobacterium tuberculosis. This prompted us to conduct a study to determine the concordance resistance pattern between aminoglycosides and the macrocyclic peptide capreomycin.A total of 2383 mycobacterial strains isolated from suspected MDR cases were subjected to susceptibility testing with aminoglycosides (kanamycin and amikacin), the polypeptide capreomycin, and ofloxacin to determine the resistance pattern. Cultures and susceptibility testing were performed using an automated BACTEC MGIT 960 instrument. Positive susceptibility samples were confirmed by PCR.The results showed that, of the total 2383 strains, 844 (35.41%) were susceptible to all four drugs, and 1539 (64.58%) strains showed resistance in the form of multi- or mono-resistance. The results also showed that of the 474 kanamycin-resistant mycobacterial strains, 86.7% and 77.6% were resistant to amikacin and capreomycin, respectively. Conversely, of the 425 amikacin- resistant mycobacterial strains, 3.3% were susceptible to kanamycin. Our findings suggest that performing susceptibility testing for individual drugs within a class may not provide an accurate strain status and may not be sufficient to make clinical decisions. It is necessary to conduct susceptibility testing of all MDR-TB strains with all aminoglycoside and macrocyclic peptide drugs before subjecting patients to comprehensive drug therapy

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-02-12
DOI
https://doi.org/10.5281/zenodo.14868928
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS

Zenodo (CERN European Organization for Nuclear Research)
Mycobacterium research and diagnosis
article

INCONGRUENT RESISTANCE TO AMINOGLYCOSIDES IN MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS

article en

Abstract

Since the discovery of the bactericidal activity of aminoglycosides, streptomycin, kanamycin, amikacin, and capreomycin (a macrocyclic peptide) have been widely used to treat tuberculosis and multidrug-resistant (MDR) tuberculosis. In general practice, resistance to kanamycin is often used as the sole criterion for defining extensively drug-resistant tuberculosis, assuming that all other drugs in this group or related drugs are resistant to certain strains. However, the assumption of cross-resistance between drugs in the same group is not always true for Mycobacterium tuberculosis. This prompted us to conduct a study to determine the concordance resistance pattern between aminoglycosides and the macrocyclic peptide capreomycin.A total of 2383 mycobacterial strains isolated from suspected MDR cases were subjected to susceptibility testing with aminoglycosides (kanamycin and amikacin), the polypeptide capreomycin, and ofloxacin to determine the resistance pattern. Cultures and susceptibility testing were performed using an automated BACTEC MGIT 960 instrument. Positive susceptibility samples were confirmed by PCR.The results showed that, of the total 2383 strains, 844 (35.41%) were susceptible to all four drugs, and 1539 (64.58%) strains showed resistance in the form of multi- or mono-resistance. The results also showed that of the 474 kanamycin-resistant mycobacterial strains, 86.7% and 77.6% were resistant to amikacin and capreomycin, respectively. Conversely, of the 425 amikacin- resistant mycobacterial strains, 3.3% were susceptible to kanamycin. Our findings suggest that performing susceptibility testing for individual drugs within a class may not provide an accurate strain status and may not be sufficient to make clinical decisions. It is necessary to conduct susceptibility testing of all MDR-TB strains with all aminoglycoside and macrocyclic peptide drugs before subjecting patients to comprehensive drug therapy

Zenodo (CERN European Organization for Nuclear Research)
Universidade de São Paulo (BR)
Good health and well-being
Openalex Percentile: Top 45%
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.